Introduction {#sec1-1}
============

Diabetes is on rise,\[[@ref1]\] imposing a significant risk of cardiovascular morbidity and mortality.\[[@ref2]\] In a majority, hypertension coexists and protective pharmacotherapy is used\[[@ref3]\] that offers cardioprotection as published by us. Nonhypertensive diabetics are monitored for brachial blood pressure (bBP) and not offered cardioprotective pharmacotherapy.\[[@ref4][@ref5]\] Hence, progression of cardiovascular aging continues in them adding to suboptimum glycemic control. There are limitations of bBP measurement. Aortic blood pressure, central hemodynamics, and arterial stiffness overcome these limitations.\[[@ref6][@ref7]\] Pulse wave analysis (PWA)--based devices like Mobil-O-Graph provide an opportunity to measure the same. We performed PWA study in type 2 diabetics not receiving antihypertensive medication.

Materials and Methods {#sec1-2}
=====================

Study design {#sec2-1}
------------

Study protocol was first approved by the institutional review board of our college. We conducted a case--control study on patients of medicine outdoor patient department of a tertiary care teaching government hospital affiliated to a government medical college.

Study participants {#sec2-2}
------------------

The sample size was calculated by Raosoft software (free online software; Raosoft, Inc., Seattle, WA, USA). To have 95% confidence level, 5% precision, considering diabetes prevalence of 7%, a sample size of 148 was adequate for a city with a population of 6 lakhs. We included apparently healthy, nonathletic, type 2 diabetics taking antidiabetics regularly since at least 6 months, not taking any antihypertensives, age ≤65 years, of either sex, nonsmoking, nonalcoholic, not known to have any acute or chronic systemic disease, and ready for written informed consent. We screened and enrolled 208 diabetics by simple random sampling. We excluded 9 irregular diabetics, 19 with use of life style modification, 4 owing to irregular pulse wave recording, 24 with body mass index (BMI) that cannot be matched with any healthy control, and 4 due to arm circumference beyond available cuff size. Hence, the case group finally had 148 cases. For comparison, we selected 148 apparently healthy, nondiabetic normotensive subjects from the available pool of 1226 healthy controls.

Subject assessment and definitions {#sec2-3}
----------------------------------

All participants were interviewed personally regarding general features, demographic characteristics, risk factors; self-reported moderate physical activity, and relevant disease history. Detailed history of pharmacotherapy used was elicited from each and regularity was confirmed by patient\'s case report chart. Systolic blood pressure (SBP) ≥140 mmHg and diastolic blood pressure (DBP) ≥90 mmHg or use of antihypertensive medication was defined as hypertension. SBP \< 140 mmHg and DBP \<90 mmHg was taken as blood pressure control. Glycemic control was defined as per American Diabetes Association guidelines 2018\[[@ref8]\] based on fasting plasma glucose (FPG \< 130 mg/dL) and 2-h plasma glucose (2 hPG \< 180 mg/dL).

Instrument used {#sec2-4}
---------------

We used portable, personal computer--attached, calibrated, and validated instrument Mobil-O-Graph (IEM GMBH, Stolberg, Germany) of the physiology department to record brachial pulse wave. It undergoes oscillometric pressure PWA as per the protocol designed by the European Society of Hypertension. Pressure oscillations are generated by brachial arterial pulsation which are transmitted to bBP cuff and measured by transducer to be fed into the microprocessor. Computerized software records pulse wave of brachial artery and by validation a generalized transfer factor derives central aortic pulse wave. It further undergoes point- and area-based analysis by a computer to derive various cardiovascular parameters.\[[@ref9]\]

Measurement protocol {#sec2-5}
--------------------

A blood pressure cuff of appropriate size (mid arm circumference: 20--24 cm = small size, 24--32 cm = medium size, 32--38 cm = large size) was chosen based on measured mid arm circumference and applied to left arm using standard protocol. All readings were taken after rest for 10 min, in the postabsorptive phase with the subjects avoiding smoking or alcohol for 12 h before measurement, in a calm room without external influences or avoiding arm movement.\[[@ref9]\]

Parameters measured {#sec2-6}
-------------------

1)Heart rate (HR), BMI, body surface area (BSA)2)bBP -- systolic (bSBP), diastolic (bDBP), pulse (bPP), and mean (bMBP)3)Central blood pressure (cBP) -- systolic (cSBP), diastolic (cDBP), pulse (cPP)4)Central hemodynamics -- cardiac output (CO), cardiac index (CI), peripheral resistance (PR)5)Arterial stiffness -- augmentation pressure (AP), augmentation index at HR 75/min, reflection magnitude percentage (Ref %), aortic pulse wave velocity.

Parameters derived {#sec2-7}
------------------

1)Rate pressure product -- (HR per minute) × (SBP) × 10^−\ 2^2)Stroke volume (SV) -- CO/HR3)Stroke volume index (SVI) -- SV/BSA4)Stroke work (SW) -- (pulse pressure) × (SV) × 0.01445)Total arterial stiffness (TAS) -- pulse pressure/SV6)Pulse pressure index -- pulse pressure/SBP7)Pulse pressure amplification -- brachial pulse pressure/aortic pulse pressure.

Results {#sec1-3}
=======

The case and control groups (*n* = 148 each) had comparable age, sex distribution, anthropometry, and physical activity status. Cases (mean diabetes duration 4.32 years, 35% glycemic control) were significantly shorter than controls. Cases showed significantly higher brachial hemodynamics (all), arterial stiffness (only PWV and TAS), and central hemodynamics (CO and PR) than controls \[[Table 1](#T1){ref-type="table"}\]. In the case group, we further compared males (*n* = 73) and females (*n* = 75). They were comparable for age, weight, BMI, duration, and glycemic control. Females had significantly shorter stature, smaller BSA, and lesser prevalence of physical activity. HR and arterial stiffness (except PWV) were significantly higher while SV was significantly lower in females than males, while parameters of brachial hemodynamics (except DBP, MBP), arterial stiffness (except PWV), and other central hemodynamics (only CO and CI) were comparable between females and males \[[Table 1](#T1){ref-type="table"}\].

###### 

Compassion of baseline and study parameters between cases and matched controls, and male cases versus female cases

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter, unit                 Cases (*n*=148)   Controls (*n*=148)   *P*               Male cases (*n*=73)   Female cases (*n*=75)   *P*
  ------------------------------- ----------------- -------------------- ----------------- --------------------- ----------------------- -------------------------
  Age, years                      52.75±7.29        52.42±7.78           0.63              52.84±7.78            52.67±6.82              0.99

  Male, no. (%)                   73 (52%)          73 (59%)             1.000             \-                    \-                      \-

  Height, cm                      160.83±6.24       162.56±6.48          **0.0013\***      163.15±5.31           158.57±6.28             **\<0.0001\***

  Weight, kg                      63.82±9.47        63.36±8.27           0.21              65.33±9.60            62.36±9.17              0.08

  BMI, kg/m^2^                    24.66±3.05        24.37±3.11           0.29              24.52±3.25            24.80±2.86              0.45

  BSA, m^2^                       1.68±0.16         1.69±0.13            0.49              1.72±0.16             1.65±0.16               0.0172\*

  P A, no. (%)                    28 (32%)          24 (17%)             0.65              19 (32%)              9 (17%)                 0.0362\*

  Duration, years                 4.32±4.51         \-                   \-                4.78±4.81             3.86±4.18               0.11

  FPG, mg/dl                      159.23±61.22      \-                   \-                150.22±52.66          168.00±67.74            0.18

  2 hPG, mg/dl                    228.93±88.17      \-                   \-                219.38±77.25          238.21±97.26            0.41

  G C, no (%)                     53 (35%)          \-                   \-                29 (35%)              24 (36%)                0.39

  bBP (mmHg)                                                                                                                             

   SBP\                           134.55±17.26\     127.66±17.07\        **0.0001\***\     134.26±17.86\         134.82±16.76\           0.84\
   DBP\                           86.26±10.18\      84.51±11.82\         **0.18\***\       86.93±10.66\          85.63±9.72\             0.43\
   MBP\                           108.22±12.26\     104.20±13.03\        **0.0021\***\     108.29±13.75\         108.16±11.85\           0.95\
   PP\                            48.40±12.83\      43.15±12.29\         **\<0.0001\***\   47.56±13.26\          49.23±12.43\            0.43\
   PPI                            0.36±0.06         0.33±0.07            **0.0058\***      0.35±0.07             0.36±0.06               0.28

  HR, bpm                         93.64±13.31       88.30±14.10          **0.0009\***      91.19±14.13           96.01±12.10             **0.0272\***

  RPP, mmHg.bpm                   125.63±13.31      112.53±22.85         **\<0.0001\***    121.62±27.39          129.53±23.49            **0.06**

  Art stiffneAP, mmHg                                                                                                                    

   Ref (%)\                       9.59±5.75\        8.75±5.27\           0.17\             7.92±4.98\            11.24±6.00\             **\<0.0001\*0.0259\***\
   AIx\@75 (%)\                   65.52±7.55\       64.95±5.98\          0.48\             64.12±7.16\           66.88±7.72\             **\<0.0001\*0.66**\
   PWV, m/s\                      34.31±11.75\      32.02±11.31\         0.20\             29.18±10.25\          39.31±10.98\            **0.0245\***\
   TAS, mL/mmHg\                  7.84±1.09\        7.52±1.17\           **0.0139\***\     7.88±1.15\            7.80±1.05\              **0.0355\***
   PPA                            0.86±0.20\        0.77±0.20\           **\<0.0001\***\   0.82±0.23\            0.90±0.16\              
                                  1.34±0.15         1.32±0.14            0.13              1.32±0.12             1.35±0.18               

  c BP (mmHg)                                                                                                                            

    cSBP\                         124.47±15.93\     118.78±15.70\        **0.0004\***\     123.66±16.43\         125.25±15.49\           0.43\
    cDBP\                         87.90±10.56\      85.99±11.73\         0.14\             88.51±10.82\          87.31±10.39\            0.49\
    cPP\                          36.68±10.60\      33.09±10.70\         **0.0005\***\     35.62±10.44\          37.71±10.72\            0.23\
    cPP ≥40, no. (%)              55 (35%)          27 (13%)             **0.0005\***      23 (62%)              32 (78%)                0.18

  Central hemodynamics                                                                                                                   

   CO, L/min\                     5.26±0.81\        4.89±0.70\           **\<0.0001\***\   5.32±0.90\            5.20±0.72\              0.39\
   PR, mm Hg/mL\                  1.25±0.13\        1.29±0.15\           **0.0043\***\     1.24±0.16\            1.26±0.10\              0.41\
   CI, L/min/m^2^ SV, mL/beat\    3.13±0.55\        2.90±0.43\           **\<0.0001\***\   3.09±0.61\            3.17±0.49\              0.50\
   SVI, mL/m^2^/beat SW, g/beat   56.80±10.20\      56.62±10.99\         0.90\             58.80±12.12\          54.84±8.99\             **0.0252\***\
                                  34.05±7.12\       33.57±6.48\          0.44\             34.62±8.12\           33.49±6.00\             0.34\
                                  117.88±34.43      105.55±30.66         0.07              115.34±33.55          107.94±28.61            0.16
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

Bold values: Statistically significant with *P*\<0.05. BMI: body mass index; PA: physical activity; FPG: fasting plasma glucose; 2 hPG: 2-h plasma glucose; GC: glycemic control; bBP: brachial blood pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure; MBP: mean blood pressure; PP: pulse pressure; PPI: pulse pressure index; HR: heart rate RPP: rate pressure product; AP: augmentation pressure; Ref: reflection percentage; AIx\@75: augmentation index at heart rate 75 beats/min; PWV: pulse wave velocity; TAS: total arterial stiffness; PPA: pulse pressure amplification; cSBP: central systolic blood pressure; cDBP: central diastolic blood pressure; cPP: central pulse pressure; CO: cardiac output; PR: peripheral resistance; CI: cardiac index; SV: stroke volume; SVI: stroke volume index; SW: stroke work '\*' indicates statistical significance. Bold data indicates statistically significant with *P*\<0.05

Physically active cases had significantly better profile of PWA parameters than matched and comparable physically inactive cases, with statistical significance for most brachial, cBPs, arterial stiffness parameters, and SW. When compared with cases with BMI \< 23, cases with BMI ≥ 23 had significantly higher values of arterial stiffness and PR. The former group had insignificantly higher brachial and cBP than the latter group \[[Table 2](#T2){ref-type="table"}\].

###### 

Comparison of baseline and study parameters between subgroups of cases based on physical activity (present or absent) and BMI (cut-off 23)

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter, unit                 PA+ (*n*=28)    PA− (*n*=28)    *P*               BMI\<23 (*n*==42)   BMI≥23 (*n*==42)   *P*
  ------------------------------- --------------- --------------- ----------------- ------------------- ------------------ -------------------------------
  Age, years                      52.36±6.77      52.54±8.45      0.94              52.93±7.71          52.79±7.81         0.93

  Male, no. (%)                   19 (52%)        19 (59%)        1.00              23 (52%)            23 (59%)           1.00

  Height, cm                      161.39±6.21     161.79±5.97     0.81              160.64±6.46         161.14±5.85        0.71

  Weight, kg                      64.79±9.60      64.54±9.20      0.95              54.95±5.16          65.26±6.19         **\<0.0001\***

  BMI, kg/m^2^                    24.89±3.56      24.62±2.77      0.76              21.28±1.26          25.21±1.71         **\<0.0001\***

  BSA, m^2^                       1.69±0.19       1.70±0.14       0.82              1.57±0.12           1.71±0.13          **\<0.0001\***

  P A, no. (%)                    \-              \-              \-                6 (32%)             8 (17%)            0.77

  Duration, years                 3.83±3.73       4.66±4.41       0.47              3.40±3.15           4.33±4.10          0.29

  FPG, mg/dL                      159.04±61.79    168.89±72.12    0.52              147.31±39.58        148.55±55.10       0.54

  2 hPG, mg/dL                    230.39±92.23    233.03±75.59    0.64              212.5±76.70         216.48±81.69       0.88

  G C, no. (%)                    13 (35%)        8 (36%)         0.27              15 (35%)            19 (36%)           0.51

  bBP (mmHg)                                                                                                               

   SBP\                           126.50±12.85\   137.79±21.57\   **\<0.0209\***\   136.57±18.33\       132.62±18.34\      0.63\
   DBP\                           83.89±8.81\     84.93±14.00\    0.74\             88.38±8.28\         84.81±10.49\       0.13\
   MBP\                           102.57±8.86\    109.18±16.45\   **0.0447\***\     110.26±11.83\       106.67±13.27\      0.55\
   PP\                            43.21±10.08\    52.68±13.88\    **0.0044\***\     48.19±14.29\        47.81±12.00\       0.90\
   PPI                            0.34±0.06       0.38±0.07       **0.0158\***      0.35±0.06           0.36±0.05          0.45

  HR, bpm                         92.68±14.77     93.54±12.04     0.81              92.17±12.98         93.76±12.13        0.56

  RPP, mmHg.bpm                   117.56±24.51    128.51±25.12    0.0963            124.65±29.52        123.97±21.80       0.90

  Art stiffness                                                                                                            

   AP, mmHg\                      6.39±3.41\      10.79±6.38\     **0.0022\***\     8.92±6.99\          12.23±7.34\        **\<0.0001\*0.0006\***\
   Ref (%)\                       63.54±7.05\     66.43±7.72\     0.15\             64.27±7.98\         67.30±7.21\        **\<0.0001\*0.74\<0.0001\***\
   AIx\@75 (%)\                   28.82±11.62\    35.25±13.43\    **0.0374\***\     29.85±11.47\        35.91±10.95\       **0.0031\***
   PWV, m/s\                      7.31±1.08\      7.9±1.18\       **0.0183\***\     7.90±1.08\          7.49±1.06\         
   TAS, mL/mmHg\                  0.79±0.18\      0.91±0.20\      **0.0304\***\     0.78±0.23\          6.84±0.22\         
   PPA                            1.40±0.13       1.30±0.12       **0.0072\***      1.37±0.19           1.33±0.16          

  cBP (mmHg)                                                                                                               

   cSBP\                          116.00±11.07\   127.82±19.28\   **0.0068\***\     126.45±16.13\       122.09±17.25\      0.24\
   cDBP\                          85.07±8.87\     86.93±14.39\    **0.56**\         90.45±8.51\         86.31±11.33\       0.13\
   cPP\                           31.11±7.26\     40.89±11.31\    **0.0003\***\     36.00±11.68\        35.43±10.05\       0.81\
   cPP ≥40, no. (%)               2 (35%)         14 (13%)        **0.0008\***      15 (62%)            13 (78%)           0.82

  Central hemodynamics                                                                                                     

   CO, L/min\                     5.03±0.68\      5.44±1.02\      0.08\             5.26±0.91\          5.29±0.74\         0.44\
   PR, mmHg/mL\                   1.24±0.12\      1.22±0.15\      0.54\             1.28±0.13\          1.22±0.15\         **0.0076\***\
   CI, L/min/m^2^ SV, mL/beat\    2.96±0.47\      3.20±0.59\      0.09\             3.36±0.61\          3.07±0.50\         0.07\
   SVI, mL/m^2^/beat SW, g/beat   55.17±9.31\     59.05±13.35\    0.21\             57.17±13.16\        57.14±9.58\        0.99\
                                  33.15±6.96\     34.75±8.00\     0.43\             36.58±8.66\         33.61±6.06\        0.07\
                                  101.24±22.99    119.89±40.05    **0.0371\***      114.41±38.41        110.77±29.66       0.63
  --------------------------------------------------------------------------------------------------------------------------------------------------------

PA+: physical activity present; PA−: physical activity absent; the remaining abbreviations are the same as [Table 1](#T1){ref-type="table"}. Bold data indicates statistically significant with *P*\<0.05

Good glycemics and poor glycemics were comparable for baseline and PWA parameters. Cases with disease duration of \>4 years had no significantly different profile of study parameters when compared with those with a duration of ≤4 years \[[Table 3](#T3){ref-type="table"}\].

###### 

Comparison of baseline and study parameters between subgroups of cases based on blood pressure control (present or absent) and duration (cut-off 5)

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter, unit                 GC+ (*n*=48)      GC− (*n*=48)    *P*              Dn ≤4 years (*n*=88)   Dn \>4 years (*n*=60)   *P*
  ------------------------------- ----------------- --------------- ---------------- ---------------------- ----------------------- ----------------
  Age, years                      51.46±6.69        51.46±6.44      0.84             51.54±7.08             54.52±7.29              **0.0118\***

  Male, no. (%)                   25 (52%)          25 (59%)        1.00             40                     33                      0.31

  Height, cm                      161.98±5.25       160.54±7.16     0.27             160.22±5.95            161.73±6.60             0.25

  Weight, kg                      64.83±10.42       64.04±9.50      0.65             63.32±9.96             64.57±8.72              0.17

  BMI, kg/m^2^                    24.75±3.60        24.80±2.81      0.81             24.64±3.35             24.70±2.58              0.38

  BSA, m^2^                       1.71±0.17         1.68±0.15       0.30             1.67±0.17              1.71±0.15               0.13

  P A, no. (%)                    11 (32%)          6 (17%)         0.28             19 (32%)               9 (17%)                 0.39

  Duration, years                 4.51±4.34         4.69±5.35       0.84             1.56±1.00              8.35±4.63               **\<0.0001\***

  FPG, mg/dL                      108.79±10.79      180.23±46.58    **\<0.0001\***   158.88±60.93           159.75±62.16            0.81

  2 hPG, mg/dL                    150.94±16.68      255.25±82.66    **\<0.0001\***   228.49±90.47           204.69±87.04            **0.0322\***

  G C, no. (%)                    48 (35%)          0 (36%)         \-               29 (35%)               24 (36%)                0.39

  bBP (mmHg)                                                                                                                        

   SBP\                           134.10±17.82\     134.98±17.49\   0.80\            133.80±18.73\          135.65±14.91\           0.52\
   DBP\                           85.81±9.69\       86.85±9.79\     0.60\            86.69±11.25\           85.62±8.44\             0.53\
    MBP\                          107.69±11.94\     108.88±11.89\   0.63\            108.06±13.74\          108.45±9.80\            0.39\
    PP\                           48.65±12.67\      48.13±14.16\    0.85\            47.31±12.54\           50.01±13.19\            0.15\
    PPI                           0.36±0.06         0.35±0.07       0.58             0.35±0.06              0.36±0.07               0.17

  HR, bpm                         91.04±13.29       93.85±13.58     0.31             93.24±12.81            94.22±14.12             0.66

  RPP, mmHg.bpm                   120.47±25.45      126.98±26.51    0.22             124.13±27.08           127.83±23.61            0.39

  Art stiffness                                                                                                                     

  AP, mmHg  \                     9.29±5.60\        9.83±5.67\      0.55\            9.56±5.68\             9.63±5.90\              0.99\
  Ref (%)\                        65.21±7.77\       66.25±8.84\     0.54\            65.55±7.78\            65.48±7.26\             0.68\
   AIx\@75 (%)\                   33.31±9.25\       35.46±14.16\    0.20\            34.70±12.12\           33.73±12.26\            0.62\
   PWV, m/s\                      7.66±1.06\        7.73±1.00\      0.72\            7.74±1.10\             7.98±1.09\              0.20\
   TAS, mL/mmHg\                  0.86±0.22\        0.84±0.20\      0.96\            0.85±0.20\             0.87±0.21\              0.54\
   PPA                            1.35±0.14         1.33±0.17       0.84             1.32±0.12              1.36±0.18               0.06

  cBP (mmHg)                                                                                                                        

   cSBP\                          123.58±15.49\     129.85±16.28\   0.70\            124.48±17.38\          124.45±13.66\           0.70\
   cDBP\                          86.75±10.22\      88.69±10.05\    0.35\            88.14±11.79\           87.55±8.52\             0.35\
   cPP\                           36.46±10.14 17\   36.90±11.57\    0.84\            36.22±10.75\           37.35±10.43 24\         0.84\
   Cpp ≥40, no. (%)               (35%)             20 (13%)        0.68             31 (62%)               (78%)                   0.68

  Central h emodynamics                                                                                                             

   CO, L/min\                     5.23±0.79\        5.28±0.92\      0.75\            5.20±0.87\             5.30±0.73\              0.09\
   PR, mmHg/mL\                   1.25±0.14\        1.25±0.19\      0.98\            1.26±0.14\             1.22±0.11\              0.18\
    CI, L/min/m^2^\               3.06±0.60\        3.15±0.57\      0.48\            3.11±0.59\             3.17±0.48\              0.30\
   SV, mL/beat\                   57.55±11.03\      57.31±12.52\    0.92\            56.00±10.24\           57.97±11.56\            0.28\
   SVI, mL/m^2^/beat SW, g/beat   34.09±8.06\       34.36±7.62\     0.87\            33.91±6.88\            34.24±7.52\             0.78\
                                  112.87±33.25      112.91±34.24    \>0.99           109.70±32.81           111.38±30.29            0.38
  --------------------------------------------------------------------------------------------------------------------------------------------------

GC+: glycemic control present; GC−: glycemic control absent; Dn: duration; the remaining abbreviations are the same as Table 1. Bold data indicates statistically significant with *P*\<0.05

By multiple linear regression models, we tested for predictors of major PWA parameters (dependent parameters) from independent study parameters. HR was the consistent predictor of arterial stiffness (except for PWV) and central hemodynamics (except cPP). Age was a major positive predictor only for PWV. bMBP and bPP were significant predictors but not for all dependent parameters. Duration was a significant negative predictor for PWV, cSBP, and cPP, and positive predictor for SW. Height, weight, BMI, SBP (except for cDBP), DBP, FPG, and two hPGs were not significant predictors. Most bBPs were not significant predictors of corresponding cBPs \[[Table 4](#T4){ref-type="table"}\].

###### 

Calculation of predictors for dependent variables by multiple linear regression (rpartial values) in case group

  Parameters   AP            AIx\@75        aPWV          TAS            cSBP          cDBP            cPP           CO           SW
  ------------ ------------- -------------- ------------- -------------- ------------- --------------- ------------- ------------ ---------------
  Age          0.05          0.10           0.11\*\*      0.00           0.05          0.02            0.00          −0.01        −0.21
  Height       0.18          −0.43          0.03          −0.00          −0.11         0.08            −0.11         0.02         0.21
  Weight       0.07          0.26           −0.04         0.00           0.05          −0.10           0.09          −0.02        −0.13
  BMI          −0.19         −0.95          0.08          −0.01          0.02          0.13            −0.00         0.06         0.49
  SBP          −0.73         −1.85          0.05          −0.02          0.44          **0.84\*\***    −0.31         0.09         2.51
  DBP          −0.08         0.01           0.01          0.00           0.06          0.09            0.01          0.00         −0.10
  MBP          **0.82\***    **1.88\***     −0.03         0.01           0.50          0.08            0.33          −0.06        −0.94
  HR           **−0.05\***   **0.44\*\***   −0.00         **0.01\*\***   **−0.04\***   **0.02\***      −0.04         **0.01\***   **−0.85\*\***
  PP           0.63          1.25           −0.01         **0.02\***     0.17          **−0.82\*\***   **0.91\***    −0.02        −0.46
  Duration     −0.13         −0.27          **−0.02\***   0.00           **−0.19\***   −0.00           **−0.17\***   0.02         **0.54\***
  FPG          0.01          0.01           0.00          0.00           0.01          0.00            0.01          −0.00        −0.02\*
  2hPG         −0.00         −0.01          0.00          −0.00          −0.01         0.00            0.00          0.00         0.01

BMI: body mass index; PA: physical activity; FPG: fasting plasma glucose; 2 hPG: 2-h plasma glucose; GC: glycemic control; bBP: brachial blood pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure; MBP: mean blood pressure; PP: pulse pressure; PPI: pulse pressure index; HR: heart rate RPP: rate pressure product; AP: augmentation pressure; Ref: reflection percentage; AIx\@75: augmentation index at heart rate 75 beats/min; PWV: pulse wave velocity; TAS: total arterial stiffness; PPA: pulse pressure amplification; cSBP: central systolic blood pressure; cDBP: central diastolic blood pressure; cPP: central pulse pressure; CO: cardiac output; PR: peripheral resistance; CI: cardiac index; SV: stroke volume; SVI: stroke volume index; SW: stroke work '\*' indicates statistical significance. Bold data indicates statistically significant with *P*\<0.05

Discussion {#sec1-4}
==========

This is by far the first Mobil-O-graph-based study on urban Indian diabetics. Oscillometric PWA using generalized transfer factor provides details of cardiovascular health and aging, beyond routinely and subjectively measured bBP.\[[@ref10][@ref11]\] We included diabetics not receiving any antihypertensive therapy that allowed us to study the effect of diabetes before there is incident hypertension or its correction. We compared treated diabetics with controls from the same setup using the same recording device with proven reproducibility.

Cases showed higher brachial, central hemodynamics, and arterial stiffness than controls despite antidiabetic therapy and absence of hypertension. Higher results in diabetics can also be explained by poor glycemic control despite therapy which is the feature of our diabetics.\[[@ref12]\] Such results are in line with a study done elsewhere.\[[@ref13]\] It can also be due to (1) unavailability of HbA1c that gives better inference about glycemic control, (2) higher prevalence of physical inactivity, (3) poor blood pressure control, (4) ethnic predisposition, (5) delayed diagnosis, and (6) lack of life style modification. Diabetes and hypertension are interrelated,\[[@ref14]\] and we found the same in treated diabetics in whom cardiovascular aging is not prevented by use of drugs such as beta blocker\[[@ref5]\] or drugs affecting renin--angiotensin aldosterone system.\[[@ref4]\] This accelerated cardiovascular profile indicates the increase in work load on heart that can produce adverse effect on itself and other target organ damages.\[[@ref15]\] Raised arterial stiffness indicates future risk of hypertension that is a very common aftermath of diabetes.\[[@ref14]\]

Females had significantly higher values of PWA parameters mainly arterial stiffness, in line with our previous studies on normotensives\[[@ref10][@ref16]\] and hypertensives\[[@ref11]\] in middle-aged group. The mean age of 52 years explains female disadvantage of postmenopausal age in most of the female cases.\[[@ref17]\] Apart from gender-specific and sex hormone--specific differences, these results can be viewed in light of shorter stature, higher physical inactivity, and higher mean HR in females. Raised stiffness and accelerated hemodynamics indicate beyond aging cardiovascular risk in postmenopausal females compared with premenopausal women.

Self-reported moderate physical activity and controlled BMI had significant positive impact on PWA results in line with a previous study.\[[@ref18]\] This indicates the importance of obesity and its correction by physical activity as a potential to explore in diabetics without incident hypertension. These two are modifiable risk factors that must be corrected by all. Adiposity is one of the factors affecting vascular aging, hence PWA parameters.\[[@ref19]\]

Hyperglycemia accelerates cardiovascular aging that manifests as raised stiffness, reduced compliance, and loss of elasticity.\[[@ref20]\] And diagnosis and treatment of the same is supposed to benefit these parameters as published previously. Contrastingly, lack of impact glycemic control was found. It can be explained by ethnicity risk, lack of HbA1c result, and poor glycemic control (40%) in most cases. Our results are similar to Gordin\[[@ref21]\] *et al*. and Chang\[[@ref22]\] *et al*. In previous studies, we found that arterial stiffness was significantly raised in young first-degree relatives of diabetic\[[@ref6]\] or hypertensive\[[@ref7]\] parents and so the vascular change may precede the incident diabetes or hypertension. It supports the idea that diabetes is more a disease affecting cardiovascular health with hyperglycemia being a late manifestation. We did not find significant difference between new or old cases and with duration less than or more than 4 years with respect to PWA parameters, in line with our previous studies in diabetics with different cardiovascular parameters.\[[@ref12][@ref23][@ref24][@ref25][@ref26]\] It indicates the importance of presence of disease, early diagnosis, physical activity, and prompt treatment more than further chronicity or glycemic control.

We studied predictors of the major study parameters by multiple linear regressions. The pattern of predictors was similar to our previous PWA studies.\[[@ref6][@ref7][@ref10][@ref11][@ref16][@ref27]\] The major points were as follows: (1) most outcome parameters were not significantly predicted by age (except PWV), height, weight, and BMI; (2) most of these were independent of bBPs pointing toward superiority of these parameters to complement routinely measured objective bBP; (3) HR proved to be the most consistent predictor which normally one can infer from pulse examination and proves the potential of details that can be obtained by arterial pulse examination; and (4) cBPs were not predicted significantly by the corresponding brachial artery values showing its importance beyond bBP.

Hypertension with coexisting or causative type 2 diabetes is one of the frequent encounters to a family physician. Routine bBP sometimes do not infer to more direct cardiovascular parameters. Physician can take advantage of PWA that offers better understanding of cardiovascular aging. We have established trends, association, and predictors of PWA parameters for our population. Central hemodynamics and arterial stiffness are stable, reliable, reproducible, objective, direct, discrete parameters. With availability of devices like Mobil-O-graph, it can be offered on large-scale and even at primary care level. This baseline work asks for further vertical and interventional studies to reinforce our results and to ascertain role of other risk factors not studied as limitations of our study.

There were few limitations of our study like cross-sectional nature, moderate sample size, lack of baseline data or follow-up, and absence of biochemical investigations.

Conclusion {#sec1-5}
==========

Oscillometric PWA shows adverse profile of beyond bBP direct and discrete cardiovascular parameters in Gujarati diabetics not using any antihypertensive medication. This vascular progeria in the absence of hypertension and antihypertensive use was independent of duration and glycemic control, related to gender, BMI, and physical activity. This baseline study suggests further work on these potential parameters.
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